Skip to main content

Aclara Reports Flat Revenues, Widened Losses

SAN FRANCISCO, Nov. 7 - Aclara BioSciences today reported approximately flat revenue for the third quarter of 2002.


The company said its total revenue was $505,000 in the third quarter which ended September 30, compared to $507,000 in the same quarter of 2001.


Aclara reported a net loss based on generally accepted accounting principles of $11.2 million, or $.31 per share, in the third quarter 2002 compared to a net loss of $9.1 million, or $.26 per share, in the year-ago period. The company said the increased loss in part reflects higher costs associated with a focus on the commercialization of its eTag assay systems, a move the company said deemphasizes microfluidic product development and lead to the firing of approximately 50 employees.


R&D spending decreased to $5.4 million compared to $5.8 million in the same period a year ago.


Aclara also reported $85.2 million in cash, cash equivalents, and short-term investments at the end of September 2002.


Click here for more information.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.